Cost-Effectiveness Studies Support Medtronic's HeartWare HVAD

A cost-effectiveness analysis of the LATERAL trial shows patients treated with Medtronic’s HeartWare HVAD through the less-invasive thoracotomy procedure incurred lower hospitalization and medical supply costs than patients implanted with a ventricular assist device through the traditional sternotomy approach. Another new analysis shows HeartWare HVAD is more cost-effective than ventricular assist devices of the past.

HVAD Beauty 3Reflect with golf ball
Medtronic HeartWare HVAD • Source: Medtronic PLC

[Editor's note: Complete historical information on important medical device trial announcements is available from Informa’s MedDeviceTracker. For an archive of previous Medtech Insight articles on medtech clinical trials, visit the Tracking Trials page.]

Two new cost-effectiveness studies support the cost-effectiveness of Medtronic PLC’s HeartWare HVAD intrapericardial centrifugal left-ventricular assist device (LVAD) for...

More from R&D

More from Business